Skip to main content

Table 2 Analysis of maximum CRT across all treatments

From: A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities

Toxicity

n (Univariable analysis)

n (Multivariable analysis)

BCSS

RFS

Unadjusted

Adjusted

Unadjusted

Adjusted

HR (95 % CI)

P value

HR (95 % CI)

P value

HR (95 % CI)

P value

HR (95 % CI)

P value

Neutropeniaa

5886

5211

0.85 (0.74–0.98)

0.02

0.87 (0.75–1.01)

0.06

0.85 (0.76–0.95)

0.004

0.86 (0.76–0.97)

0.02

Nausea

6248

5468

1.11 (0.93–1.33)

0.25

1.09 (0.90–1.33)

0.37

1.07 (0.91–1.25)

0.42

1.06 (0.90–1.26)

0.47

Vomiting

6248

5468

0.98 (0.80–1.19)

0.80

1.03 (0.84–1.28)

0.76

1.00 (0.85–1.18)

>0.99

1.05 (0.88–1.26)

0.57

Stomatitis

6248

5468

1.20 (0.89–1.63)

0.24

1.25 (0.90–1.74)

0.19

1.09 (0.83–1.43)

0.54

1.12 (0.83–1.50)

0.46

Constipation

5886

5211

0.91 (0.80–1.04)

0.17

0.95 (0.82–1.09)

0.45

0.91 (0.82–1.01)

0.09

0.94 (0.83–1.05)

0.27

Diarrhoea

6248

5468

0.93 (0.68–1.26)

0.64

0.98 (0.70–1.38)

0.93

1.08 (0.85–1.37)

0.54

1.19 (0.92–1.55)

0.18

Infection

6248

5468

1.09 (0.97–1.22)

0.14

1.01 (0.90–1.15)

0.82

1.06 (0.96–1.16)

0.26

1.01 (0.91–1.12)

0.88

Fatigue

6248

5468

1.24 (1.07–1.43)

0.004

1.17 (0.99–1.37)

0.06

1.17 (1.03–1.32)

0.01

1.13 (0.99–1.30)

0.08

Anaemia

3943

3582

1.18 (0.97–1.42)

0.09

1.14 (0.93–1.39)

0.21

1.11 (0.95–1.30)

0.20

1.08 (0.91–1.28)

0.36

Combined haematological

3943

3582

0.89 (0.77–1.03)

0.11

0.88 (0.76–1.03)

0.12

0.88 (0.78–0.99)

0.03

0.88 (0.78–1.00)

0.06

Neurotoxicity

3943

3582

0.96 (0.82–1.13)

0.64

0.99 (0.84–1.17)

0.90

0.98 (0.86–1.12)

0.78

0.99 (0.87–1.14)

0.94

Myalgia

3943

3582

0.95 (0.82–1.09)

0.43

1.03 (0.89–1.20)

0.69

0.95 (0.84–1.06)

0.34

1.02 (0.91–1.16)

0.70

Fever

3943

3582

0.98 (0.67–1.44)

0.91

0.84 (0.57–1.26)

0.41

1.08 (0.80–1.46)

0.63

0.98 (0.71–1.34)

0.88

  1. BCSS Breast cancer-specific survival; RFS Relapse-free survival; HR Hazard ratio; CI Confidence interval
  2. aCases classified as National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEAE) grade ≥3
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us